Affiliation: University of Heidelberg
- Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumoursI Buchmann
Department of Nuclear Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany
Eur J Nucl Med Mol Imaging 34:1617-26. 2007..The aim of our study was to compare the value of (68)Ga-DOTATOC PET and (111)In-DTPAOC SPECT (Octreoscan) in the detection of NET manifestations...
- Influence of cell proportions and proliferation rates on FDG uptake in squamous-cell esophageal carcinoma: a PET studyInga Buchmann
Klinik und Poliklinik fur Nuklearmedizin, Universitätskliniken Mainz, Mainz, Germany
Cancer Biother Radiopharm 23:172-80. 2008..We investigated the influence of cell proportions and proliferation activities on tumor maximum standard uptake value (SUV(max)) in patients with squamous-cell esophageal cancer (SCEC)...
- [[18F]-FDG-PET in the diagnostics of gastrointestinal tumors]I Buchmann
Abteilung für Nuklearmedizin, Universitätskliniken Heidelberg, Heidelberg
Z Gastroenterol 46:367-75. 2008..For gastrointestinal stroma tumours, FDG-PET is useful for the monitoring of therapy and the initial staging. For imaging of hepatocellular carcinoma and carcinoma of the gall bladder, FDG-PET is not sufficient...
- Comparison of 99mtechnetium-pertechnetate and 123iodide SPECT with FDG-PET in patients suspicious for breast cancerInga Buchmann
Department of Nuclear Medicine, University of Heidelberg, Heidelberg, Germany
Cancer Biother Radiopharm 22:779-89. 2007....
- FDG-PET in the initial staging of squamous cell oesophageal carcinomaI Buchmann
Nuclear Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany
Nuklearmedizin 45:235-41. 2006..Squamous cell oesophageal carcinoma is the most common carcinoma of the oesophagus worldwide. The tumour stage as most important prognostic factor determines the clinical management...
- 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trialI Buchmann
Department of Nuclear Medicine, Ulm University Hospital, Ulm, Germany
Cancer 91:889-99. 2001....
- Different radiosensitivity of smooth muscle cells and endothelial cells in vitro as demonstrated by irradiation from a Re-188 filled balloon catheterJ Kotzerke
Department of Nuclear Medicine, University of Ulm, D 89070, Ulm, Germany
Atherosclerosis 152:35-42. 2000..Within 18 h after irradiation no effect on cytoskeletal components and vWF was documented. This in vitro study demonstrates that irradiation inhibits HCMSMC and HCPSMC at lower dose rates compared to HCAEC...
- Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity?A C Buck
Department of Nuclear Medicine, University of Ulm, Ulm, Germany
J Nucl Med 42:721-5. 2001..The aim of this prospective study was to evaluate a probable correlation between FDG uptake and proliferative activity in benign and malignant pancreatic tumors...
- [18F]5-fluoro-2-deoxyuridine-PET for imaging of malignant tumors and for measuring tissue proliferationInga Buchmann
Abteilung für Nuklearmedizin, Universittskliniken Ulm, Germany
Cancer Biother Radiopharm 18:327-37. 2003..FdUrd-PET was less effective than FDG-PET. In this group of patients, it was not useful in measuring tissue proliferation...
- [18F]3'-deoxy-3'-fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations--a pilot studyInga Buchmann
Nuklearmedizin, Universitatskliniken, Ulm, Germany
Cancer Biother Radiopharm 19:436-42. 2004..We prospectively evaluated the biodistribution of the PET tracer [18F]3'-deoxy-3'-fluorothymidine (FLT) and its value in detecting manifestations of non-Hodgkin's lymphoma (NHL)...
- FDG PET for imaging pericardial manifestations of Hodgkin lymphomaInga Buchmann
Abteilung für Nuklearmedizin, Universitätskliniken Ulm, Deutschland
Clin Nucl Med 28:760-1. 2003..These findings and computed tomographic findings were suspicious for manifestations of Hodgkin lymphoma. The pericardial findings were demonstrated on F-18 fluorodeoxyglucose positron emission tomographic imaging...
- Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia: results of a phase I-II studyThorsten Zenz
Haematologica 91:285-6. 2006..The intensified conditioning was not associated with increased non-relapse mortality. No reduction in the incidence of relapse was observed in the context of a T-cell depleted graft (4-year overall survival: 29%)...
- Radiolabeled peptides and proteins in cancer therapyCarmen Wängler
Department of Nuclear Medicine, University of Heidelberg, German Cancer Research Centre DKFZ, Germany
Protein Pept Lett 14:273-9. 2007..Future generations of endoradiopharmaceuticals will address yet unknown targets which might be identified by screening techniques such as ribosome and phage display peptide libraries...
- A comparison of the biodistribution and biokinetics of (99m)Tc-anti-CD66 mAb BW 250/183 and (99m)Tc-anti-CD45 mAb YTH 24.5 with regard to suitability for myeloablative radioimmunotherapyInga Buchmann
Department of Nuclear Medicine, University Hospital, Ulm, Germany
Eur J Nucl Med Mol Imaging 30:667-73. 2003..Thus, it appears superior to anti-CD45 mAb YTH 24.5 in selectively increasing the marrow dose and avoiding extramedullary organ toxicity...
- Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicitiesInga Buchmann
Department of Nuclear Medicine, University Hospital, Ulm, Germany
Cancer Biother Radiopharm 17:151-63. 2002..We evaluated biodistribution, radiation absorbed organ doses and immediate toxicities of myeloablative radioimmunotherapy with marrow selective 188rhenium (188Re)-labeled anti-CD66 monoclonal antibody (mAb)...
- 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II studyMark Ringhoffer
Department of Internal Medicine III, University of Ulm, Ulm, Germany
Br J Haematol 130:604-13. 2005..In conclusion, radioimmunotherapy using the anti-CD66 antibody was feasible and safe in our elderly patient group and provided a high marrow dose...